This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in New Haven, CT, Alexion Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of life-transforming drugs, for the treatment of patients with ultra-rare disorders. The company’s complement franchise consists of key growth driver, Soliris, which is approved for the treatment of two severe and ultra-rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system — paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Soliris is also approved for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. The FDA also approved its long-acting C5 complement inhibitor, Ultomiris, for the treatment of adult patients with PNH, to be administered every eight weeks. In October 2019, the FDA approved the use of Ultomiris as a treatment for adult and pediatric (one month of age or older) patients with aHUS to inhibit complement-mediated TMA.
Biotech Stock Roundup: GILD Epclusa's China Approval, BMRN Palynziq's FDA Nod
by Zacks Equity Research
The biotech sector grabbed headlines last week with drug approvals and licensing deals. Investors will await pipeline development news at the ASCO in the coming week.
Why is Alexion (ALXN) Down 3.5% Since its Last Earnings Report?
by Zacks Equity Research
Alexion (ALXN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Achillion (ACHN) Posts Wider-Than-Expected Q1 Loss, Names CEO
by Zacks Equity Research
Achillion Pharmaceuticals (ACHN) disappoints with wider-than-expected loss in the first quarter. Appoints Joseph Truitt as new CEO.
Biotech Stock Roundup: ALXN, VRTX Post Solid Results, GILD Disappoints in Q1
by Zacks Equity Research
The biotech sector was in focus over the last five trading sessions as several bigwigs like Gilead and Vertex, among others reported results while some others provided pipeline updates.
Strength Seen in Alexion Pharmaceuticals (ALXN): Stock Soars 14.5%
by Zacks Equity Research
Alexion (ALXN) was a big mover last session, as the company saw its shares rise more than 14% on the day amid huge volumes.
Alexion's (ALXN) Earnings Beat Estimates in Q1, Guidance Up
by Zacks Equity Research
Alexion exceeds both earnings and sales expectations in the first quarter of 2018.The company also raised revenue and earnings guidance for 2018.
Alexion (ALXN) Tops Q1 Earnings and Sales Beat Estimates
by Zacks Equity Research
Alexion surpassed earnings and revenue expectations in the first quarter of 2018.
What's in the Cards for BioMarin (BMRN) in Q1 Earnings?
by Zacks Equity Research
BioMarin (BMRN) is likely to see continued momentum in Kuvan and Vimizim sales. On the call, management is likely to comment on the launch preparation for pegvaliase.
Why Alexion Pharmaceuticals (ALXN) Might Surprise This Earnings Season
by Zacks Equity Research
Alexion Pharmaceuticals (ALXN) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Is a Beat in Store for Alexion (ALXN) This Earnings Season?
by Zacks Equity Research
Impressive sales of Alexion's blockbuster drug, Soliris might lead the company toward an earnings beat in Q1.
Alexion Pharmaceuticals, Inc. (ALXN) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) Sees Hammer Chart Pattern: Time to Buy?
Amgen (AMGN) to Report Q1 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
While Amgen's (AMGN) growth drugs like Prolia & Xgeva might do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.
What's in Store for Biogen (BIIB) This Earnings Season?
by Zacks Equity Research
On the Q1 call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance.
Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics
by Zacks Equity Research
The biotech space was a witness to a series of events. while share price of several stocks moved up, a few fell substantially.
Pharma M&A Active This Week: 4 Potential Buyout Targets
by Indrajit Bandyopadhyay
Novartis and Alexion announce respective acquisitions of AveXis and Wilson Therapeutics for a pipeline boost. We suggest four stocks as hot acquisition picks this year.
Alexion (ALXN) to Acquire Wilson Therapeutics for $855M
by Zacks Equity Research
Alexion (ALXN) announces that the company will acquire Sweden-based Wilson Therapeutics for $855 million, the latest company to join the ongoing acquisitions spree in the biotech sector.
Biotech Stock RoundUp: ALXN & ARNA Up on Study Data, PRTA Teams Up With Celgene
by Zacks Equity Research
The biotech sector was in focus last week with Alexion gaining on positive data on PNH candidate, Arena surges on ulcerative drug data, Solid Biosciences' stock suffering a crash and Prothena teaming up with Celgene.
Alexion (ALXN) Gains On Positive Date From Lead Candidate
by Zacks Equity Research
Alexion's (ALXN) shares gained 3.4% following positive results from a phase III study on its important candidate, ALXN1210, wherein it was compared to its lead drug Soliris.
Achillion (ACHN) Q4 Loss Widens, Plans Job Cuts to Save Cost
by Zacks Equity Research
Achillion Pharmaceuticals' (ACHN) fourth-quarter loss wider than estimates. The company is focusing on operational restructuring to save costs.
The Zacks Analyst Blog Highlights: ExxonMobil, Caterpillar, Union Pacific, Alexion and Sanofi
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ExxonMobil, Caterpillar, Union Pacific, Alexion and Sanofi
3 ETFs to Watch on Biotech Earnings
by Zacks Equity Research
Major Biotech companies report mixed Q4 results.
Alexion's (ALXN) Earnings and Sales Beat Estimates in Q4
by Zacks Equity Research
Alexion (ALXN) surpass earnings and sales estimates in the fourth quarter of 2017. The company received FDA approval for label expansion of Soliris in the United States.
Alexion (ALXN) Tops Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Alexion surpassed earnings and sales expectations in the fourth quarter of 2017.
REGN vs. ALXN: Which Stock is Poised for Better Q4 Earnings?
by Zacks Equity Research
Let's take a look at which of these biotech companies, Alexion (ALXN) or Regeneron (REGN) has an edge ahead of their Q4 release.
Why Earnings Season Could Be Great for Alexion Pharmaceuticals (ALXN)
by Zacks Equity Research
Alexion Pharmaceuticals (ALXN) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.